Letters and public comments:

Letter of Doctors for America, Consumer, Patient, and Healthcare Provider Organizations, and Experts on Drug Regulation to the Senate Health, Education, Labor and Pensions (HELP) Committee recommending legislation strengthening the accelerated approval pathway and ensuring clinical trial diversity (May 20, 2022).

Letter of Doctors Without Borders/Médecins Sans Frontières (MSF) USA; Doctors for America; Drugs for Neglected Diseases initiative (DNDi), North America; Knowledge Ecology International; and Christopher Morten to OSTP, HHS, NIH, and BARDA, “The US Government Should Disclose the Costs of Clinical Trials it Funds to Make Medical Tools Affordable, Accessible, and Suited to Public Health Needs” (January 31, 2022).

Comments of Christopher Morten, James Krellenstein & Christian Urrutia on NIST’s proposed changes to regulations governing “Rights to Federally Funded Inventions and Licensing of Government Owned Inventions” (April 5, 2021). 

Letter of academics & activists urging NIH to use government-owned patents to increase vaccine access (March 24, 2021).

Letter of researchers, scholars, professionals, and activists to Secretary Alex Azar, seeking disclosure of trial protocols and other information on COVID-19 vaccine candidates (October 20, 2020).

Comments of Christopher Morten on FDA’s “Listing of Patent Information in the Orange Book” (August 30, 2020).

A Time for Solidarity”: Open letter of scholars on anti-Black racism and defunding the police (August 24, 2020).

Letter led by the COVID-19 Working Group of New York City to the National Institutes of Health, “The NIH must not cancel awarded grants for purely political reasons” (May 11, 2020).

Letter of Doshi et al. re: Docket No. FDA-2019-N-2012 (“New Drugs Regulatory Program Modernization: Improving Approval Package Documentation and Communication”) (August 23, 2019). 

Letter of Amy Kapczynski and Christopher Morten to the House Oversight Committee in connection with HOC’s hearing, “HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments” (May 16, 2019). 



Chemistry publications: 

Mousseau, J. J.; Morten, C. J.; Jamison, T. F. “A Dioxane Template for Highly Selective Epoxy Alcohol Cyclizations,” Chem. Eur. J. 2013, 19, 10004-16.

Morten, C. J.; Byers, J. A.; Jamison, T. F. “Evidence that Epoxide-Opening Cascades Promoted by Water Are Stepwise and Become Faster and More Selective After the First Cyclization,” J. Am. Chem. Soc. 2011, 133, 1902-08.

Morten, C. J.; Byers, J. A.; Van Dyke, A. R.; Vilotijevic, I.; Jamison, T. F. “The Development of Endo- Selective Epoxide-Opening Cascades in Water,” Chem. Soc. Rev. 2009, 38, 3175-92.

Morten, C. J.; Jamison, T. F. “New Strategies for the Stereocontrolled Synthesis of Substituted ʻSkippedʼ Diepoxides,” Tetrahedron 2009, 65, 6648-55.

Morten, C. J.; Jamison, T. F. “Water Overcomes Methyl Group Directing Effects in Epoxide-Opening Cascades,” J. Am. Chem. Soc. 2009, 131, 6678-79.







Mark